Clinical Trials Logo

Filter by:
NCT ID: NCT04933721 Active, not recruiting - Clinical trials for Hereditary Angioedema

Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

APeX-A
Start date: July 23, 2021
Phase: Phase 3
Study type: Interventional

This is a phase 3b open-label study providing access to berotralstat for HAE patients who were previously enrolled in berotralstat studies.

NCT ID: NCT04933695 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

CodeBreaK201
Start date: January 28, 2022
Phase: Phase 2
Study type: Interventional

The main objective of this study is to evaluate the tumor objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in participants who receive sotorasib at either 960 mg daily or 240 mg daily whose tumors are programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) < 1% and/or harbor a serine/threonine kinase 11 (STK11) co-mutation, in a subgroup of participants with PD-L1 < 1% and in a subgroup of participants with STK11 co-mutation.

NCT ID: NCT04933513 Completed - Parkinson's Disease Clinical Trials

Development and Validation of a Scale Measuring Preoperative Expectations in Parkinson's Disease

Start date: March 30, 2022
Phase:
Study type: Observational

Subthalamic nucleus deep brain stimulation (STN-DBS) has become a choice treatment for fluctuating Parkinson's disease (PD) patients, inducing remarkable improvement in motor symptoms. However, as PD is a complex neuropsychiatric disease, it has been hypothesized that in some patients, non-motor features, i.e. dysfunctional expectations for the result of neurosurgery, could interfere with postoperative result of DBS, even in case of motor improvement. Recent literature highlights the necessity to take these preoperative expectations into account, but to our knowledge, no specific scale investigating these cognitions in this PD-specific condition is available. So, the investigators developped the DBS-PS, a self-scale constructed to measure preoperative expectations for DBS, with 11 questions and visuo-analogical responses (1 to 10), theorically divided in three domains investigating the expectations concerning symptoms of PD, postoperative social-life and leisures, and postoperative familial and marital sphere. The investigators would like to validate this new-developped scale in the preoperative subthalamic nucleus deep brain stimulation population through patients recruited in the Predistim study, whereas the investigators did not recruite sufficiently patients through the PsyParkinson study, the one in which the DBS-PS scale was developed. The DBS-PS constitutes an interesting basis for the consideration of these cognitive and affective factors in preoperative PD patients.

NCT ID: NCT04933344 Recruiting - Clinical trials for Bone and Joint Infection

Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections

PKTOXDAP
Start date: June 15, 2021
Phase:
Study type: Observational

the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection

NCT ID: NCT04933097 Completed - Clinical trials for Rheumatoid Arthritis

Evaluation of a New Screening Method for Sarcopenia in Rheumatoid Arthritis

SARCO-RA
Start date: July 29, 2021
Phase: N/A
Study type: Interventional

Evaluation of a new screening method for sarcopenia in rheumatoid arthritis

NCT ID: NCT04932941 Completed - COVID-19 Clinical Trials

MP1032 Treatment in Patients With Moderate to Severe COVID-19

Start date: October 19, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).

NCT ID: NCT04932837 Withdrawn - SARS-COV-2 Clinical Trials

Level of Immunity, Neutralization of the COVID-19 Virus and Reinfections in Residents of 2 Migrant Workers' Residences

Start date: June 14, 2021
Phase:
Study type: Observational

A previous seroprevalence survey showed very high seroprevalence levels among residents of the two among the residents of the two migrant workers' hostels surveyed, indicating a high level of circulation of the virus SARS-COV-2 during the 1st wave of COVID-19. The constitution of a cohort after the event would be an opportunity to obtain opportunity to obtain answers to crucial questions: duration of immunity, potential reinfections potential reinfections, potential re-clustering. Going back to check the serological status seems feasible, especiallyespecially in the Foyers de Travailleurs Migrants (high probability of finding the participants). There is an obvious scientific interest around the duration of immunity and reinfections in a population highly exposed during the first wave. Several articles document the decline of IgG antibodies in the months following an infection, but very few infection, but very few evaluate the protective character in the medium term (>=6 months), especially in asymptomatic individuals. We are also concerned about the circulation of We are also concerned about the circulation of new variants and the immunity acquired after infection in residents. To date, no study on the duration of immunity has been conducted in migrant worker's residences.

NCT ID: NCT04932603 Recruiting - Atrial Fibrillation Clinical Trials

Multidisciplinary Team Approach to Prescribe Antithrombotic Therapy in Older People With Atrial Fibrillation

ANTITHROMBOTEA
Start date: June 14, 2021
Phase:
Study type: Observational

Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, are used to prevent and treat many cardiovascular disorders. With the increase in prevalence of cardiovascular diseases and medical progress, these treatments are increasingly being prescribed, particularly in older patients. One of the main indications of antithrombotic drugs is atrial fibrillation (AF), a disease highly prevalent in older people, a population at high risk of adverse drug events. Notably, antithrombotic drugs are the first involved in serious adverse drug events, among which 40-70% may be preventable. In this context, six units of the hospital group "Assistance Publique - Hôpitaux de Paris" have created a multidisciplinary team which assesses antithrombotic prescriptions in older patients with AF. This team, gathering geriatricians, cardiologists, neurologists and haematologist specialized in haemostasis, evaluates the patient medical profile and suggests the most appropriate antithrombotic treatment based on their expertise and the available recommendations. Here we want to look at patients outcomes in light of the intervention of this multidisciplinary team.

NCT ID: NCT04932590 Recruiting - Shock Clinical Trials

Predicting Fluid Responsiveness During Shock in Newborns and Infants by End-expiratory Occlusion Test

EVEOC
Start date: December 24, 2021
Phase: N/A
Study type: Interventional

To date, the end-expiratory occlusion test in infants or children has never been evaluated as a marker of preload dependence. It therefore appears clinically relevant to evaluate this new indicator to predict fluid responsiveness in all infants hospitalized in pediatric and neonatal intensive care. The main objective of this study is to determine whether the hemodynamic effects of a 15-second end-expiratory occlusion were able to predict fluid responsiveness in the mechanically ventilated infant or newborn in pediatric intensive care.

NCT ID: NCT04932525 Recruiting - Clinical trials for Solid Tumor, Unspecified, Adult

Gustave Roussy Cancer Profiling

STING
Start date: May 10, 2021
Phase: Phase 1
Study type: Interventional

The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +/- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.